RxDoctor Payments Data

Nazal Obaid, MD

Cardiovascular Disease · Portage, INNPI 1891797064

Payments from drug & device makers

$16,449in general payments, 2019–2025

Across 547 payments — averaging $30.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • W. L. Gore & Associates, Inc.$2K
  • Philips North America LLC$1K
  • Merck$895
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$814
  • EKOS Corporation$731
  • plus $9K from 44 others

What the payments were for

  • Travel & lodging$1,5169%
  • Food & beverage$14,86090%
  • Education$730%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,449 in reported general payments places this provider in the 75th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$212,268
Medicare patients
1,700
Services billed
4,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban266$307,619
EntrestoSacubitril/Valsartan179$231,697
XareltoRivaroxaban187$228,422
MultaqDronedarone Hcl25$57,871
JardianceEmpagliflozin42$44,976
BrilintaTicagrelor56$41,422
Repatha SureclickEvolocumab50$34,305
FarxigaDapagliflozin Propanediol25$22,422
NexlizetBempedoic Acid/Ezetimibe26$19,656
Praluent PenAlirocumab19$9,477
Amiodarone Hcl147$7,608
Sildenafil Citrate13$7,307
Metoprolol Succinate574$6,935
VascepaIcosapent Ethyl19$6,591
Dexlansoprazole DrDexlansoprazole17$6,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$229$307,619266 claims
NovartisEntresto$2,226$231,697179 claims
Johnson & JohnsonXarelto$569$228,422187 claims
AstraZenecaBrilinta, Farxiga$553$63,84581 claims
Sanofi-aventis U.S. LLCMultaq$362$57,87125 claims
Boehringer IngelheimJardiance$689$44,97642 claims
Esperion Therapeutics, Inc.Nexlizet$605$19,65626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Portage

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →